News Releases

Search by year or by keyword :

Date	Title
2024-11-11	Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
2024-10-28	Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets
2024-10-07	Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
2024-09-25	Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
2024-09-23	Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
2024-09-17	Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
2024-09-03	Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
2024-08-19	Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
2024-08-09	Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
2024-07-26	Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug

United States:

Taiwan: